|
Apr 25
|
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
|
|
Apr 25
|
Regeneron (REGN) Reports Next Week: What You Should Expect
|
|
Apr 25
|
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
|
|
Apr 25
|
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
|
|
Apr 25
|
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
|
|
Apr 25
|
Regeneron expands in gene editing with Mammoth deal
|
|
Apr 24
|
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
|
|
Apr 24
|
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
|
|
Apr 22
|
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
|
|
Apr 22
|
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
|
|
Apr 19
|
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
|
|
Apr 18
|
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
|
|
Apr 17
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Apr 16
|
Why Regeneron (REGN) Could Beat Earnings Estimates Again
|
|
Apr 15
|
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
|
|
Apr 15
|
Regeneron to defend against DOJ complaint on drug-price manipulation
|
|
Apr 15
|
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
|
|
Apr 15
|
Regeneron commits $500M to new venture capital fund
|
|
Apr 14
|
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
|